SCHEMBL25651310

SCHEMBL25651310

CCCC(NC(=O)CCCCCCCCCCCCCCCCCCC(=O)O)C(=O)O

nearest known ligand 0.69

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ NOD1 Q9Y239 8/20 0.69
▸ PLA2G2C Q5R387 1/20 0.55
▸ SLC6A5 Q9Y345 2/20 0.55
▸ PLA2G10 O15496 2/20 0.54
▸ GNPAT O15228 1/20 0.53
▸ ALDH1A1 P00352 2/20 0.50
▸ FAAH O00519 2/20 0.49
▸ MEN1 O00255 1/20 0.49
▸ MAPK1 P28482 1/20 0.49
▸ KMT2A Q03164 1/20 0.49
▸ TSHR P16473 1/20 0.48
▸ SLC22A6 Q4U2R8 1/20 0.48
▸ SLC22A8 Q8TCC7 1/20 0.48
▸ GPR84 Q9NQS5 1/20 0.48
▸ PPARG P37231 1/20 0.48
▸ PPARD Q03181 1/20 0.48
▸ PPARA Q07869 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL71687 1.00 NOD1 (0.69) NOD1PLA2G2CSLC6A5PLA2G10GNPAT
SCHEMBL8292791 1.00 NOD1 (0.69) NOD1PLA2G2CSLC6A5PLA2G10GNPAT
SCHEMBL29329833 1.00 NOD1 (0.69) NOD1PLA2G2CSLC6A5PLA2G10GNPAT
SCHEMBL14478728 1.00 NOD1 (0.69) NOD1PLA2G2CSLC6A5PLA2G10GNPAT
SCHEMBL18560506 1.00 NOD1 (0.69) NOD1PLA2G2CSLC6A5PLA2G10GNPAT
SCHEMBL23601770 1.00 NOD1 (0.69) NOD1PLA2G2CSLC6A5PLA2G10GNPAT
SCHEMBL18783045 1.00 NOD1 (0.69) NOD1PLA2G2CSLC6A5PLA2G10GNPAT
SCHEMBL14685779 1.00 NOD1 (0.69) NOD1PLA2G2CSLC6A5PLA2G10GNPAT
SCHEMBL14725995 1.00 NOD1 (0.69) NOD1PLA2G2CSLC6A5PLA2G10GNPAT
SCHEMBL18573779 0.97 NOD1 (0.74) NOD1PLA2G2CSLC6A5PLA2G10GNPAT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230190879-A1 DUAL-AGONIST COMPOUND FOR BOTH GLP-1 AND GIP RECEPTORS AND APPLICATION THEREOF JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) 2023-06-22 — — US disclosed
EP-4177263-A1 NOVEL POLYPEPTIDE AND THERAPEUTIC USE THEREOF Vitalixir (Beijing) Co., Ltd (CN) 2023-05-10 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230190879-A1 DUAL-AGONIST COMPOUND FOR BOTH GLP-1 AND GIP RECEPTORS AND APPLICATION THEREOF GLP1R, GIPR, GPR119 NOD1 1106/4885PLA2G2C 838/4885SLC6A5 316/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback